Loading patent…
AssigneesAstraZeneca Pharmaceuticals LP, Amylin Pharmaceuticals, Inc.
InventorsOdile Esther Levy, Alain D. Baron, Lawrence J. D'Souza, Mary Erickson, Soumitra G. Ghosh, Michael R. Hanley, Samuel Janssen, Carolyn M. Jodka, Diana Y. Lewis, Christine M. Mack, David G. Parkes, Richard A. Pittner, Christopher J. Soares, Ved Srivastava, Andrew A. Young, Thao Le
Estimating the term…
The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
A compound comprising the amino acid sequence of SEQ ID NO:186.
A compound comprising the amino acid sequence of SEQ ID NO:186, SEQ ID NO:902, SEQ ID NO:907, SEQ ID NO:908, SEQ ID NO:876, SEQ ID NO:877, SEQ ID NO:878, SEQ ID NO:872, SEQ ID NO:873, SEQ ID NO:874, SEQ ID NO:875, or SEQ ID NO:859.
Dependencies are inferred from the claim text.